(NASDAQ: BCTX) Briacell Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.78%.
Briacell Therapeutics's earnings in 2025 is -$19,621,152.On average, 1 Wall Street analyst forecast BCTX's earnings for 2025 to be -$17,821,122, with the lowest BCTX earnings forecast at -$17,821,122, and the highest BCTX earnings forecast at -$17,821,122. On average, 1 Wall Street analyst forecast BCTX's earnings for 2026 to be -$11,993,683, with the lowest BCTX earnings forecast at -$11,993,683, and the highest BCTX earnings forecast at -$11,993,683.
In 2027, BCTX is forecast to generate -$9,757,572 in earnings, with the lowest earnings forecast at -$9,757,572 and the highest earnings forecast at -$9,757,572.